Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer Previous studies suggest that besides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results